Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 1, 2017, Pages 81-89

  Yang, Ming Chin ^a   Tan, Elise Chia Hui ^a   Su, Jian Jhih ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Department of Forensic Medicine   (Taiwan)

Author keywords

cost effectiveness; Influenza vaccine; Quadrivalent influenza vaccine (QIV); Quality adjusted life year (QALYs); Taiwan; Trivalent influenza vaccine (TIV)

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE PLANNING; HEALTH SERVICE; HUMAN; POST EXPOSURE PROPHYLAXIS; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SEASONAL INFLUENZA; SENSITIVITY ANALYSIS; ADOLESCENT; ADULT; AGE; AGED; CHILD; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; IMMUNOLOGY; INFANT; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PROCEDURES; TAIWAN; UTILIZATION; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TAIWAN; VACCINATION; YOUNG ADULT;

EID: 84996482953     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1225636     Document Type: Article

References (40)

1. Chang CW, Wu KB, Huang ZM, Chen CH. Prevalence of influenza virsus between Taiwan and other contries (in Chinese). Taiwan Epidemiol Bull 2006; 22:813-27.
2. World Health Organization. Vaccine use. 2013.
3. National Health Insurance Administration. Catastrophic Illness definition of National Health Insurance. 2011.
4. Lee PI. Influenza Vaccine. Taipei, Taiwan:Centers for Disease Control, Department of Health, R.O.C (Taiwan); 2011.
5. Centers for Disease Control and Prevention. Seasonal influenza activity surveillance reports:1999–2000 to 2010–2011 seasons. Atlanta, USA.
6. Chang C-W, Chuang R-H, Wu K-B. Epidemiological Analysis of Seasonal Influenza Epidemic in Taiwan in 2006/2007. Epidemiol Bull 2008; 24:876-89.
7. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-8; PMID:22226861; http://dx.doi.org/10.1016/j.vaccine.2011.12.098
8. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30:7443-6; PMID:23084849; http://dx.doi.org/10.1016/j.vaccine.2012.10.025
9. Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 2006; 24:4934-41; PMID:16678945; http://dx.doi.org/10.1016/j.vaccine.2006.03.057
10. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of age. Vaccine 2006; 24:1035-43; PMID:16183177; http://dx.doi.org/10.1016/j.vaccine.2004.12.033
11. Newall AT, Scuffham PA, Kelly H, Harsley S, MacIntyre CR. The cost-effectiveness of a universal influenza vaccination program for adults aged 50–64 years in Australia. Vaccine 2008; 26:2142-53; PMID:18343537; http://dx.doi.org/10.1016/j.vaccine.2008.01.050
12. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age:Cost-effectiveness of rapid testing and antiviral therapy. Annal Int Med 2003; 139:321-9; http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00007
13. Hoshi SL, Kondo M, Honda Y, Okubo I. Cost-effectiveness analysis of influenza vaccination for people aged 65 and over in Japan. Vaccine 2007; 25:6511-21; PMID:17681651; http://dx.doi.org/10.1016/j.vaccine.2007.05.067
14. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004; 13:437-52; PMID:15127424; http://dx.doi.org/10.1002/hec.864
15. George B, Harris A, Mitchell A. Cost effectiveness analysis and the consistency of decision making - Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001; 19:1103-9; PMID:11735677; http://dx.doi.org/10.2165/00019053-200119110-00004
16. Bridges JFP, Onukwugha E, Mullins CD. Healthcare Rationing by Proxy Cost-Effectiveness Analysis and the Misuse of the $50 000 Threshold in the US. Pharmacoeconomics 2010; 28:175-84; PMID:20067332; http://dx.doi.org/10.2165/11530650-000000000-00000
17. Van Bellinghen LA, Meier G, Van Vlaenderen I. The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK:A Lifetime Multi-Cohort Model. Plos One 2014; 9:e98437; PMID:24905235; http://dx.doi.org/10.1371/journal.pone.0098437
18. Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunotherap 2014; 10:1171-80; http://dx.doi.org/10.4161/hv.28221
19. You JHS, Ming WK, Chan PKS. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis. Hum Vaccin Immunotherap 2015; 11:564-71; http://dx.doi.org/10.1080/21645515.2015.1011016
20. Chit A, Roiz J, Aballea S. An assessment of the expected cost-effectiveness of quadrivalent influenza vaccines in Ontario, Canada Using a static model. Plos One 2015; 10:e0133606; PMID:26222538; http://dx.doi.org/10.1371/journal.pone.0133606
21. Meier G, Gregg M, Nautrup BP. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly:an updated analysis in the UK. J Med Econom 2015; 18:746-61; http://dx.doi.org/10.3111/13696998.2015.1044456
22. You JHS, Ming WK, Chan PK. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis 2014; 14:618; http://dx.doi.org/10.1186/s12879-014-0618-9
23. Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, Nicholson K. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67):a systematic review and economic evaluation. Health Technol Assess 2009; 13:1-+; PMID:19215705; http://dx.doi.org/10.3310/hta13110
24. Centers for Disease Control. The public poll of avian influenza immunization. e-Society Research Group 2005.
25. Lin JH, Chiu SC, Shaw MW, Lin YC, Lee CH, Chen HY, Klimov A. Characterization of the epidemic influenza B viruses isolated during 2004–2005 season in Taiwan. Virus Res 2007; 124:204-11; PMID:17196288; http://dx.doi.org/10.1016/j.virusres.2006.11.005
26. Lo YC, Chuang JH, Kuo HW, Huang WT, Hsu YF, Liu MT, Chen CH, Huang HH, Chang CH, Chou JH, et al. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011–12 season. PLoS One 2013; 8:e58222; PMID:23472161; http://dx.doi.org/10.1371/journal.pone.0058222
27. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews 2010:CD004876.
28. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2008:CD004879.
29. Chuang JH, Huang AS, Huang WT, Liu MT, Chou JH, Chang FY, Chiu WT. Nationwide surveillance of influenza during the pandemic (2009–10) and post-pandemic (2010–11) periods in Taiwan. PLoS One 2012; 7:e36120; PMID:22545158; http://dx.doi.org/10.1371/journal.pone.0036120
30. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7:iii-iv, xi-xiii, 1-170; PMID:14609480; http://dx.doi.org/10.3310/hta7350
31. Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19:834-42; PMID:11152308; http://dx.doi.org/10.1007/s100960000376
32. Chuang JH, Cheng-Hua Lee P-IL, Wu CF, Liu M-T, Su WY, Huang WT. Effectiveness of influenza A (H1N1) monovalent vaccine and trivalent inactivated influenza vaccine. Centers for Disease and Control, R.O.C. (Taiwan), 2010.
33. Centers for Disease Control. Practical guideline for prevention and control of seasonal influenza (in Chinese). Taipei City, Taiwan (R.O.C.):Centers of Disease and Control, Department of Health, 2008.
34. Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. PharmacoEconomics 2001; 19:293-301; PMID:11303417; http://dx.doi.org/10.2165/00019053-200119030-00007
35. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves:an example using data from a trial of management strategies for atrial fibrillation. Bmc Health Serv Res 2006; 6:52; PMID:16623946
36. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Db Syst Rev 2008.
37. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Db Syst Rev 2010.
38. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2010; CD001269
39. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M. Comparing influenza vaccine efficacy against mismatched and matched strains:a systematic review and meta-analysis. BMC Med 2013; 11:153; PMID:23800265; http://dx.doi.org/10.1186/1741-7015-11-153
40. Gagliardi L, Rusconi F, Galassi C, Forastiere F. Re.:“Antibiotic exposure by 6 months and asthma and allergy at 6 years:findings in a cohort of 1,401 US children”. Am J Epidemiol 2011; 173:1343; author reply 4–5; PMID:21478296; http://dx.doi.org/10.1093/aje/kwr082